CR20140216A - 5,7-imidazo[1,2-c]pirimidinas sustituidas - Google Patents

5,7-imidazo[1,2-c]pirimidinas sustituidas

Info

Publication number
CR20140216A
CR20140216A CR20140216A CR20140216A CR20140216A CR 20140216 A CR20140216 A CR 20140216A CR 20140216 A CR20140216 A CR 20140216A CR 20140216 A CR20140216 A CR 20140216A CR 20140216 A CR20140216 A CR 20140216A
Authority
CR
Costa Rica
Prior art keywords
pyrimidins
imidazo
substituted
solvates
stereoisomers
Prior art date
Application number
CR20140216A
Other languages
English (en)
Inventor
Mark Laurence Boys
Laurence E Burgess
C Todd Eary
Robert Groneberg
Bruno P Hache
Darren Harvey
Erik James Hicken
Christopher F Kraser
Ellen Laird
David A Moreno
Mark C Munson
Li Ren
John E Robinson
Stephen T Schlachter
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20140216A publication Critical patent/CR20140216A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de Fórmula I: y estereoisómeros y sales y solvatos farmacéuticamente aceptables de estos, donde R1, R2, R3, R4, R5, R6, X1 y X2 tienen los significados que se proporcionan en la memoria descriptiva, son inhibidores de una o más cinasas JAK y s
CR20140216A 2011-10-12 2014-05-09 5,7-imidazo[1,2-c]pirimidinas sustituidas CR20140216A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161546426P 2011-10-12 2011-10-12

Publications (1)

Publication Number Publication Date
CR20140216A true CR20140216A (es) 2014-08-21

Family

ID=47071473

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140216A CR20140216A (es) 2011-10-12 2014-05-09 5,7-imidazo[1,2-c]pirimidinas sustituidas

Country Status (19)

Country Link
US (1) US20140228349A1 (es)
EP (1) EP2766368A1 (es)
JP (1) JP2014528475A (es)
KR (1) KR20140076619A (es)
CN (1) CN103987713A (es)
AR (1) AR088304A1 (es)
AU (1) AU2012323399A1 (es)
BR (1) BR112014008865A2 (es)
CA (1) CA2851623A1 (es)
CL (1) CL2014000931A1 (es)
CO (1) CO6950483A2 (es)
CR (1) CR20140216A (es)
IL (1) IL231903A0 (es)
MX (1) MX2014004473A (es)
RU (1) RU2014118954A (es)
SG (1) SG11201401342VA (es)
TW (1) TW201326173A (es)
UY (1) UY34388A (es)
WO (1) WO2013055645A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231340A1 (en) 2012-03-02 2013-09-05 Sareum Limited Pharmaceutical compounds
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
WO2015032423A1 (en) * 2013-09-03 2015-03-12 Sareum Limited Pharmaceutical compounds
HUE054371T2 (hu) * 2014-12-05 2021-09-28 Array Biopharma Inc 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok
US10617690B2 (en) 2015-01-20 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitor
HUE044240T2 (hu) * 2015-04-29 2019-10-28 Wuxi Fortune Pharmaceutical Co Ltd Janus kináz (JAK) inhibitorok
UA118822C2 (uk) 2015-05-29 2019-03-11 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор янус-кінази
EP3419978B1 (en) 2016-02-24 2020-04-15 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
WO2019034973A1 (en) * 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
JP7083203B2 (ja) * 2018-06-06 2022-06-10 ジェングル セラピューティクス，インコーポレイテッド ピラゾロピリミジン誘導体、その用途並びに医薬組成物
WO2020063751A1 (en) * 2018-09-27 2020-04-02 Fochon Pharmaceuticals, Ltd. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
KR102650496B1 (ko) 2018-10-31 2024-03-26 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
CA3136468A1 (en) * 2019-04-12 2020-10-15 Primegene (Beijing) Co., Ltd. Pyrazolopyrazine derived compounds and pharmaceutical compositions used as jak inhibitors
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
US20240083900A1 (en) * 2020-11-13 2024-03-14 Biogen Ma Inc. Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors
TW202402754A (zh) 2021-03-04 2024-01-16 美商美國禮來大藥廠 Fgfr3抑制劑化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010981A1 (en) 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
ES2612196T3 (es) * 2005-12-13 2017-05-12 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
HUE026659T2 (en) * 2006-11-22 2016-07-28 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2011130146A1 (en) * 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases

Also Published As

Publication number Publication date
US20140228349A1 (en) 2014-08-14
CO6950483A2 (es) 2014-05-20
MX2014004473A (es) 2015-04-14
SG11201401342VA (en) 2014-09-26
RU2014118954A (ru) 2015-11-20
CN103987713A (zh) 2014-08-13
AU2012323399A1 (en) 2014-05-29
CL2014000931A1 (es) 2014-08-29
WO2013055645A1 (en) 2013-04-18
AR088304A1 (es) 2014-05-21
UY34388A (es) 2014-04-30
KR20140076619A (ko) 2014-06-20
IL231903A0 (en) 2014-05-28
JP2014528475A (ja) 2014-10-27
EP2766368A1 (en) 2014-08-20
TW201326173A (zh) 2013-07-01
CA2851623A1 (en) 2013-04-18
BR112014008865A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
CR20140216A (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
UY39630A (es) Inhibidores de bromodominios
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY1122272T1 (el) ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
PH12016500024A1 (en) Bromodomain inhibitor
UY33328A (es) "5,7-SUSTITUIDO-IMIDAZOL[1,2-c]PIRIMIDINAS"
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
CO2018011064A2 (es) Inhibidores de bromodominios
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
CO6361910A2 (es) Pirrolidina-2-carboxamidas sustituidas
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
CR20120643A (es) Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
UA118261C2 (uk) Хімічні сполуки
EA201301301A1 (ru) Производные тиазола
CR20140135A (es) Nuevos derivados de aril-quinolina
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
GB201209587D0 (en) Therapeutic compounds